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Autonomy of the renin system in type II diabetes meltitus: Dietary
sodium and renal hemodynamic responses to ACE inhibition. Recogni-
tion that non-insulin-dependent diabetes mellitus (NIDDM) is a leading
cause of end-stage renal disease (ESRD), and a focus of recent therapeu-
tic and genetic studies on the renin system have rekindled interest in
mechanisms by which angiotensin converting enzyme (ACE) inhibitors
influence the diabetic kidney. We evaluated the renal hemodynamic status
of 19 hypertensive patients with NIDDM under controlled sodium bal-
ance, low (10 mmol/day for 5 to 7 days) or high (200 mmol/day for 5 to 7
days). The renal plasma flow (RPF) response to ACE inhibition and to
angiotensin II (Ang II) infusion was measured as para-aminohippurate
(PAH) clearance before and during enalapril administration (10 mg b.i.d.
for 3 days). Our premise was that if renal vasodilation induced by ACET
involves kinins, prostaglandins, and/or nitric oxide, vasoconstrictor re-
sponses to Ang II would be blunted. Conversely, if the dominant ACE
inhibitor action were a reduction in Ang II formation, the consequence
would be up-regulation and an enhanced vasoconstrictor response to
exogenous Ang II. RPF in NIDDM on a high-salt diet was lower than in
age-matched controls (477 25 vs. 551 25 ml/min/1.73 m2; P = 0.02).
Enalapril increased RPF in NIDDM to 511 29 ml/min/1.73 m2 (P <
0.05) and enhanced renal vasoconstrictor responses to Mg II infusion,
from —68 9 to —106 18 ml/min/l.73 m2 (P = 0.03). Baseline plasma
renin activity (PRA) and plasma aldosterone significantly exceeded
matched normotensive controls (1.1 0.5 vs. 0.3 0.1 ng AI/ml/hr and
10 0.9 vs. 4.1 0.5 ng/dl, P < 0.01, respectively). Conversely all
measures in studies on a low-salt diet were normal. Our findings indicate
that: (I) NIDDM with hypertension is associated with reduced RPF when
dietary salt intake is high; (2) reduced Ang II formation is the dominant
mechanism of ACEI-induced renal vasodilation in hypertensives with
NIDDM; and (3) the sustained renal hemodynamic responses to ACE
inhibition despite high-salt balance, and the increased PRA suggest an
autonomous renin-angiotensin system suppressed subnormally by a high
salt diet in patients with NIDDM despite greater volume expansion.
Diabetes mellitus has become the leading cause of end-stage
renal disease (ESRD) in the U.S.A. Although the percentage of
patients with insulin dependent diabetes mellitus (IDDM) who
develop nephropathy, estimated to be 30 to 40%, is higher than
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the percentage in patients with non-insulin dependent diabetes
mellitus (NIDDM), the latter is 10-fold more prevalent and is
increasing in frequency as longevity increases.
In IDDM diabetes mellitus ACE inhibition has emerged as an
unambiguous choice for prevention and treatment of nephropathy
[1]. Multiple lines of evidence in studies that range from pharma-
cology to genetics have pointed to a role for the renin-angiotensin
system (RAS) in the pathogenesis of nephropathy [1—31. As a
possible reflection of renin system activation, there is a consistent
and striking renal vasodilator response to angiotensin converting
enzyme (ACE) inhibition in IDDM. [3] The mechanism of the
vasodilator response is unclear. Substantially less is known about
the control of the renal circulation in NIDDM. In his detailed
review of the renal hemodynamic response to ACE inhibition in
diabetes mellitus Bjorck found that only 2 of 18 studies focused on
patients with NIDDM, and neither study controlled salt intake [3].
In the current study in patients with Type II diabetes, we have
explored the contribution of the renin system to regulation of the
renal circulation through a systematic study of the effects of salt
intake on the renal vascular responses to two probes: exogenous
Ang II and ACE inhibition with enalapril. Our findings suggest an
unanticipated autonomy of Ang II formation in the response to a
liberal salt intake in NIDDM.
METHODS
Subjects
We admitted 19 patients with NIDDM and hypertension to the
General Clinical Research Center of the Brigham and Women's
Hospital to participate in ongoing protocols designed to explore
the state of the renin system in hypertension [4]. NIDDM was
diagnosed according to the National Diabetes Data Group criteria
[5, 6]. Criteria for that diagnosis included an onset of known
diabetes after the age of 30 years in a patient who had never
experienced diabetic ketoacidosis. Fasting blood glucose (FBG)
was equal to or exceeded 140 mg/dl, or a two-hour blood glucose
level during a standard oral glucose tolerance test (OG'TT) was
equal to or exceeded 200 mg/dI. The mean fasting blood sugar was
204 17 (range 85 to 299 mg/dl), and the two-hour blood glucose
during the OGTT averaged 319 26 (range 205 to 522 mg/dl).
Glycosylated hemoglobin was not measured as a routine part of
this hypertension protocol. In seven of the patients, NIDDM was
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first recognized during their evaluation for hypertension. The
mean duration of known NIDDM was 7 1 years, with a range of
ito 20 years. The treatment for hyperglycemia prior to evaluation
involved an oral hypoglycemic agent in six of the patients, and
exogenous insulin in five, along with instructions on diet.
The average age of the patients with NIDDM was 55 2 years,
and ranged from 37 to 68 years. For comparison renal hemody-
namics and the state of the renin-angiotensin system was assessed
in 25 normal volunteers who ranged in age from 19 to 79 years,
and averaged 53 4 years. There were 16 males and 3 females, 17
Caucasians, and 2 African Americans in the NIDDM patients.
Among the 25 normals, 10 were women and 4 were black. For the
normal responses to ACE inhibition with enalapril and the
influence of dietary sodium on these responses, data were ob-
tained from an identical protocol [7] that began at the same time
as enrollment for this study in diabetics. Because the normal
response was reported earlier [7], we have woven the relevant
comparative findings into the narrative and tables.
Hypertension was defined as a systolic blood pressure greater
than 140 mm Hg and a diastolic blood pressure greater than 90
mm Hg on at least three outpatient visits. Body mass index (BMI)
was calculated as the ratio of weight in kilograms to the square of
the height in meters. The mean BMI was 30 1 and the range was
23 to 38 kg/rn2 in the NIDDM patients. Serum creatinine,
urinalysis, 24-hour urine protein, catecholamines, and thyroid
function tests, and when indicated, renal angiographic studies
were employed to exclude secondary hypertension. Antihyperten-
sive medications, if previously used, were discontinued at least two
weeks before study.
Protocol sequence
After admission to the Clinical Research Center all 19 patients
received an isocaloric diet containing 10 mmol NaC1 and 100
mmol potassium, with 2000 ml of water for five to seven days.
Daily 24-hour urine collections were made for measurement of
sodium, potassium and creatinine. Low-salt balance was achieved
typically by the fifth day when 24-hour urinary sodium excretion
was less than 20 mEq. Each patient's renin status was determined
when in balance on a low-salt diet (10 mmol NaCI/day) on the
basis of plasma renin activity (PRA) after 120 minutes of upright
posture. Low-renin hypertension was defined as an individual in
balance on a 10 mmol sodium intake who had a PRA of less than
0.69 ng/liter/second (2.5 ng Ang l/ml/hr) at the end of the posture
study. By these criteria low-renin hypertension was found in 4 of
the 19 patients (21%), which is not different from the 25%
prevalence found in essential hypertension with an identical
protocol [6].
After an assessment of the renin response to the upright
position 9 subjects were randomized to remain on the low-salt diet
for further renal hemodynamic and hormonal assessment, as
described below. The other 10 were switched to an identical diet
containing 200 mmol NaCI, but otherwise unchanged. After five
to seven days, when balance had been achieved on the higher salt
intake, the renal hemodynamic and hormonal assessment was
made. Phlebotomy limits and protocol duration ruled out a study
design in which patients were studied on both diets.
After collection of appropriate samples to assess baseline renal
hemodynamic and hormonal status, the patients were studied
during an Ang II infusion, as detailed below. Immediately there-
after treatment with enalapril was initiated and continued over
three successive days. An initial dose of 5 mg was followed by
doses of 10 and 20 mg p.o. On the day of the 20 mg dose, all of the
renal hemodynamic and hormonal profile measurements were
repeated in the two to five hours after enalapril administration.
Techniques
Renal clearances. An intravenous catheter was placed in each of
the subjects' arms, one for infusion and the other for blood
sampling. Para-aminohippurate (Merck Sharp & Dohme, West
Point, PA, USA) and inulin clearances (Taylor Pharmacal Co.,
Decatur, IL, USA) were assessed [7]. The subjects were supine
and had been fasting for at least eight hours. A control blood
sample was obtained, and then loading doses of PAH (8 mg/kg)
and inulin (50 mg/kg) were given. A constant infusion of PAH and
inulin was initiated immediately at a rate of 12 mg/mm for PAH
and 30 mg/mm for inulin with a pump (IMED Corp., San Diego,
CA, USA). This infusion rate achieved plasma PAH concentra-
tions in the middle of the range in which tubular secretion
dominates excretion. At this plasma level of PAH, clearance is
independent of plasma concentration and, when corrected for
individual body surface area, represents approximately 90% of
RPF. Likewise, at the level of plasma inulin achieved, inulin
clearances reflects GFR. Plasma samples reflecting the control
clearances were obtained 60 minutes after the start of the
PAH/inulin infusion when a steady state had been achieved and at
45-minute intervals thereafter. Results of PAH and inulin clear-
ances are normalized to 1.73 of body surface area.
The filtration fraction (FF) was calculated by dividing the GFR
by the RPF and multiplying the result by 100, being its value
expressed as percentage. Renal vascular resistance (RVR) was
estimated by dividing the calculated mean arterial pressure by the
RPF, and multiplying this result by 100, being its value expressed
as units of mm Hg/min/100 ml.
Angiotensin II infusion. Ang II amide (Hypertensin; Ciba-Geigy
Corp., Pharmaceuticals Div., Summit, NJ, USA) was infused at 3
ng/kg/min for 45 minutes, using an electronic infusion pump
(Harvard Apparatus Co., Inc., Millis, MA, USA) [7]. The constant
infusion of PAH and inulin continued throughout the Ang II
infusion to assess changes in RPF and GFR. Blood pressure was
monitored every two to six minutes with an indirect recording
sphygmomanometer (Dinamap). Blood pressures were recorded
for one hour during the basal clearance studies. Blood samples
were obtained at the end of the basal PAl-I and inulin clearance
and after Ang II and were analyzed for PAH, inulin, aldosterone
and PRA. Serum sodium and potassium were measured at the
initiation and termination of the Aug II infusion. Serum creati-
nine was measured at the initiation of the clearance study.
Laboratory procedures. Blood samples were collected on ice and
spun immediately, and the plasma was frozen until the time of the
assay. Serum and urinary sodium and potassium levels were
measured by flame photometry, with lithium as an internal
standard. Serum creatinine, PAH, and inulin were measured by an
autoanalyzer technique [71. PRA and aldosterone were assayed by
radioimmunoassay techniques that have been described in detail
[8, 9].
Statistical analysis
Data are presented as the mean values with the SEM as the index
of dispersion. Statistical probability in a two sample data analysis
was assessed by the paired or unpaired t-test for normally
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Table 1. Demographic data: Non-insulin dependent diabetes mellitus (NIDDM) and normal subjects
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Normals
low salt
NIDDM
-______________
-______
NIDDM Low salt High salt
Age years 53 4 55 2 56 3 55 2
Gender
Male 15 16 7 9
Female 10 3 2 1
Race
African American 4 2 0 1
Caucasian 21 17 9 8
Body mass index kg/rn2 25 1 30 l' 28.9 1.5 31.6 1.7
Fasting blood glucose rng/dl
Mean arterial BPrnrn Hg
83 3
85 2
171 16h 181 23
102 3' 102 3
162 23
102 6
Cholesterol rng/dl 192 11 236 tia 234 17 243 10
Uric acid rng/dl 6.6 0.5 6.3 0.3 5.8 0.7 7.0 0.7
Serum creatinine ing/di 1.1 0.03 1.2 0.05 1.16 0.05 1.21 0.06
Data are shown as mean SEM.
P = 0.01 vs. normal subjects
'P < 0.001 vs. normal subjects
Table 2. Renin-aldosterone state and salt balance
Normals NIDDM (all patients) NIDDM (NREN)
Intake 10 200 10 200 10 200
N 25 25 19 10 16 9
Age 53±4 53±4 56±3 55±2 53±4 54±3
24 Hr urine sodium excretion 11 2 189 4 14 2 195 7 12 2 197 8
rnEq/day"
PRA 2.5 0.3 0.3 0.1 2.8 0.5 1.1 0.4 3.2 0.7 1.2 0.5k'
ALDO'
-
21±2.4 4.1±0.5 23±4 10±0.8 24±4 10±0.9'
P < 0.01 vs. PRA and ALDO on high-salt in normals
' NREN, normal renin state excluding low-renin patients
PRA, plasma renin activity (ng Ang I/ml/hr)
ALDO, aldosterone; plasma aldosterone concentration (ngldl)
distributed data. When indicated by a skew distribution, a small
number of observations, or variables estimated as ratios (FF and
RVR) non-parametric (Signed rank or Mann-Whitney rank sum)
tests were employed. To analyze three or more variables, one-way
ANOVA was used. As age is an independent influence on RPF,
GFR, and FF, when comparing these values in the NIDDM
subjects with the normotensive controls we also used analysis of
covariance (ANCOVA) by the least squares method for age-
adjustment of the renal hemodynamic data. When appropriate a
Kruskal-Wallis ANOVA was used. Statistical probability was also
assessed by linear regression analysis. The null hypothesis was
rejected when the P value was lower than 0.05.
RESULTS
Studies of a high salt diet
The normal subjects studied for comparisons of hormone
profile and renal hemodynamics were a good match for the
patients with NIDDM for age, gender, and race distribution
(Table 1). Body mass index, blood pressure, and fasting blood
glucose, on the other hand, were increased in the NIDDM
virtually by definition.
Renin-angiotensin-aldosterone system. Balance on a high-salt
intake induced the directionally anticipated suppression of the
renin system in both the normal subjects and the patients with
NIDDM (Table 2), but the difference in the magnitude of the
suppression in the two groups was not anticipated. Of the 19
NIDDM patients studied, 4 met the criterion for low-renin
hypertension: 3 were studied among the 9 patients in balance on
a low-salt diet, and I among the 10 on a high-salt diet. PRA in
NIDDM on a high salt diet was almost fourfold higher than
normal (1.1 0.4 vs. 0.3 0.1 ng AI/ml/hr; P < 0.01; Table 2).
The difference in plasma aldosterone concentration in the two
groups paralleled the difference in renin (10 0.9 vs. 4.1 0.5
ng/dl; P < 0.001). Inclusion of the single low-reniri hypertensive
did not change the magnitude or the statistical significance (Table
2). Differences in the activity of the renin system in the NIDDM
and normal subjects could not be attributed to the state of salt
balance. The studies were performed on an identical diet in the
same ward, and led to the same sodium excretion (Table 2).
During the transit from a low to a liberal salt intake, the patients
with NIDDM gained 1.38 0.2 kg (P < 0.02), significantly more
than the age-matched normal group (1.1 0.1 kg; P < 0.05).
Hemodynamics. RPF in the normal subjects showed the antic-
ipated negative relation to age (r = —0.67; P < 0.01; Fig. 1). RPF
in patients with NIDDM was significantly below that of the
normotensive controls by analysis of covariance (471 25 vs.
551 25 ml/min/1.73 m2; P = 0.02). The lowest RPF measured in
the NIDDM group was in the single patient with low-renin
hypertension (Fig. 1).
Baseline GFR in the NIDDM was unremarkable, averaging
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Fig. 1. Relationship between age and renal plasma flow (RPF) in normal
subjects (0) and in patients (•) with non-insulin-dependent diabetes
mellitus (NIDDM) studied on a high-salt diet. The normal subjects by
linear regression showed the anticipated, statistically significant relation to
age (r = —0.67;P < 0.01). RPF in patients with NIDDM was significantly
below normal (P = 0.02). The lowest RPF in the NIDDM was the single
patient with low-renin hypertension.
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Fig. 2. Relationship between age and filtration fraction (FE) in the same
normal subjects and patients with non-insulin-dependent diabetes melli-
tus (NIDDM), studied on a high-salt diet. FF rose with increasing age in
the normal subjects (r = 0.57; P < 0.01). FF was significantly increased in
NIDDM (P < 0.01) and the relation to age was lost.
120 8 ml/min/l.73 m2. Calculated baseline FF in the normal
controls rose with increasing age (r = 0.57; p < 0.01), but there
was no relationship between FF and age in the NIDDM patients
(r = 0.05; p = 0.89; Fig. 2). By analysis of co-variance, FF of
NIDDM was significantly higher than normotensive controls
(26 2 vs. 21 1%; P < 0.01). There was no relationship
between blood pressure level at the time of study and the renal
hemodynamic state.
Responses to ACE inhibition and to Ang II infusions. MAP did
not change with ACE inhibition (106 4 vs. 103 6 mm Hg; P =
0.14). Despite suppression of the renin system by the high salt
diet, administration of enalapril for three days induced a series of
renal hemodynamic responses in the NIDDM that included a
significant increase in RPF, from 471 25 to 511 29 ml/min/
1.73 m2 (I' < 0.05). GFR did not change significantly with
enalapril (120 8 to 113 8 ml/min/1.73 m2; P = 0.29), and so
there was a significant fall in FF, from 26 2 to 23 3% (P <
0.05) and RVR from 23 2 to 20 2 mm Hg/min/100 ml (P <
0.05). Also parallel with the ACE inhibitor action, there was a
small but consistent and statistically significant decrease in plasma
aldosterone concentration, from 10 ito 8 1 ng/dl (P < 0.05)
and a reactive rise in PRA from I 0.4 to 2 0.6 ng Ang I/mi/hr
(P < 0.05).
The influence of the ACE inhibitor in these patients contrasts
sharply with the findings in normal subjects on a high salt diet [71.
RPF did not increase significantly with enalapril (+6 35
ml/min/l.73 m2), and the ACE inhibitor did not enhance the renal
vascular response to Ang 11 (—136 21 vs. —132 24 mi/minI
1.73 m2) in the normal subjects. The baseline renal response to
Ang II in the NIDDM was substantially below normal for a high
salt diet (—68 9 ml/min/1.73 m2; P < 0.01) and the response was
enhanced substantially, to —106 18 mI/mm/I .73 m2 following
administration of the ACE inhibitor enalapril (P =0.03), despite
the high-salt diet (Tables 3 and 4).
NIDDM patients: Low-salt diet
Renin-angiotensin-aldosterone system. As opposed to the studies
on a high-salt diet, PRA and plasma aidosterone concentration
were elevated similarly by a low-salt diet in the normotensive
controls and the normal renin patients with NIDDM (Table 2).
Hemodynamics. Again, as opposed to the finding in the high-salt
group, by analysis of co-variance, there was no difference in RPF
in NIDDM hypertensives when compared with the normotensive
controls studied on a low salt diet (524 25 vs. 522 24
mi/mm/I .73 m2). GFR and FF in NIDDM on low-salt balance also
did not differ from normotensive controls (108 6 vs. 110
ml/min/1.73 m2 for GFR; P = 0.76 and 21 2 vs. 21 1% for FF;
P = 0.98).
Responses to ACE inhibition and to Ang I! infusions. The blood
pressure response to ACE inhibition, as anticipated, was signifi-
cantly larger in patients on a restricted salt intake than in patients
studied on a high salt diet (—12 vs. —4 mm Hg; P = 0.02). RPF
increased significantly with ACE inhibition in this group (from
524 25 to 578 27 ml/min/i.73 m2; P = 0.01), a response
resembling that on a high-salt diet (Table 4). Again, GFR did not
change with ACE inhibition, from 107 8 to 104 8 ml/min/1.73,
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Table 3. Effects of ACE-inhibition on the renin-aldosterone system in
NIDDM during high and low-salt balance
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d P < 0.01 by ANOVA comparing values during low and high salt
balance before and after enalapril
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Table 4. Renal hemodynamic responses to ACE inhibition in NIDDM
during high and low salt balance
High salt (N = 10)
Before After
ACE ACE
inhibition inhibition
Mean arterial pressure 106 + 4 103 6
mm Hg
RPF mI/mm/I. 73 m
RPF response to Ang II
mi/mm/I. 73 m
Olomerular filtration rate 120 8 113 6
mI/mm/i. 73 m2
Filtration fraction % 26 + 2 23 3'
Renal vascular 23 2 21 2"
resistance" mm Hg!
min/100 ml
Table 5. Low-renin hypertension in NIDDM: Hemodynamic responses
to ACE inhibition
Before ACE
inhibition
Mean arterial 104 8
pressure mm Hg
Renal plasma flow 440 23 492 37'
mi/mm/i. 73 m2
Glomerular filtration 108 8 113 11
rate mi/mEn/i. 73 m2
Filtration fraction % 25 1 23 2
Renal vascular 26 3 21 45
resistance
21 2 18 2' mm Hg/mmn/iOO ml
19 15 1 Renal vasoconstrictor 55 17 —90 26
response to Ang
II infusion
mi/mm/I. 73 m2
N = 4.
"P < 0.05 vs. baseline values before enalapril
"P < 0.01 vs. baseline values before enalapril
RPF is renal plasma flow.
'P < 0.05 vs. baseline values before enalapril
P < 0.01 vs. baseline values before enalapril
P < 0.001 vs. baseline values before enalapril
"P < 0.05 by Kruskall-Wallis ANOVA, comparing values during high
and low salt balance before and after enalapril
and so FF fell further (21 2 to 18 2%; P 0.07). Enalapril
also decreased renal vascular resistance from 24 ito 20 1 mm
Hg/min/100 ml; P < 0.01.
The reduction in baseline RPF induced by Ang II infusion at 3
ng!kg/min in the subjects in balance on a low-salt diet was —75
10 ml/min/1.73 m2, essentially identical to the response on a
high-salt diet. The enhancement of the response induced by
enalapril to —102 13 ml/minll,73 m2 was also essentially
identical to the response in the high-salt group [7].
The renal hemodynamic response to the ACE inhibitor in the
normal subjects was qualitatively similar to the responses in
NIDDM. In the normal subjects enalapril increased RPF by
114 27 ml/min/1.73 m2 (from 580 21 to 694 41 ml/min/1.73
m2), and enhanced the renal vascular response to Ang II signifi-
cantly (—73 15 to —149 21 ml/min/l.73 m2; P < 0.001).
NIDDM with low-renin hypertension
Because patients with low-renin hypertension might present
special features, and this syndrome is thought to be common in
NIDDM, we stratified our diabetic subjects by renin status
prospectively. Their hemodynamic data and the responses to
enalapril are summarized in Table 5.
Low-renin hypertension was found in 4 of 19 NIDDM (21%).
Blood pressure responses to ACE inhibition, as anticipated, were
significantly smaller in low-renin than in normal renin NIDDM
during low-salt balance (—6 2 vs. —11 1 mm Hg; P < 0.05).
Baseline age-adjusted RPF was also significantly lower in low-
renin NIDDM than in normal renin NIDDM in low salt balance
(440 23 vs. 534 25 ml/min/1.73 m2; P < 0.01).
The GFR presented no statistical difference when compared to
normal subjects or normal renin NIDDM under low or high-salt
balance. ACE inhibition also did not change the GFR. Filtration
fraction was significantly higher in low-renin than in normal renin
NIDDM on low-salt balance (25 2 vs. 19 2%; P =0.03 by the
Mann-Whitney U-test).
Renal plasma flow after enalapril increased as much in low-
renin as in normal renin NIDDM subjects independent of salt
balance status, (440 23 to 492 37 mI/mm/I .73 m2; P < 0.05,
Table 5). Ang II infusions decreased the baseline RPF by —55
17 ml/min/1.73 m2. With ACE inhibition the renal vasoconstrictor
response to Ang II infusion was —90 + 26 ml/min/1.73 m2; P =
0.16. Enalapril also decreased RVR significantly in low-renin
NIDDM (26 I to 21 4 mm Hg/min/100 ml; P < 0.05).
DISCUSSION
In this study we examined angiotensin-mediated control of the
renal circulation in patients with NIDDM, employing as our tools
the stimulus provided by changes in salt intake, responses to ACE
inhibition with enalapril, and renal vascular responses to Ang II
before and during ACE inhibition. We uncovered an unantici-
pated constellation of responses. The state of the RAA system,
renal perfusion, and the renal vascular response to both the ACE
inhibitor and Ang II were all well within normal limits in patients
with NIDDM when the studies were performed with the patients
in balance on a low salt diet. Low-renin hypertension, identified in
4 of 19 (or 21%) was no more common than is found in essential
hypertension [6].
In patients with NIDDM studied on a high salt diet, on the
other hand, a series of abnormalities in renal perfusion, and its
control, and in the renin-aldosterone system was identified, and
these abnormalities appear to he linked. RPF was low for age, and
despite suppression of the renin system by a high salt diet, RPF
rose significantly with the ACE inhibition induced by enalapril.
Despite the high salt diet, at baseline the renal vascular respon-
siveness to Ang 1! was blunted and the response to Ang 11 was
enhanced substantially by treatment with enalapril. PRA and
plasma aldosterone concentration were inappropriately elevated
despite the enhanced state of sodium balance in these patients;
the system was activated inappropriately with the exception of one
low-renin patient. Together this information suggests that there is
an essentially normal renin system and renal blood supply in the
context of stimulation provided by a low salt diet, yet a failure to
suppress PRA, plasma aldosterone concentration, and the renal
RAS on a high salt diet, which may be a form of "autonomy."
A renal vasodilator response to an ACE inhibitor by no means
necessarily reflects a reduction in Ang II formation because of the
Low salt (N = 9)
Before After
ACE ACE
inhibition inhibition
973 873h
471 25 511 29' 524 25 578 27
—68 9 106 18 —75 10—102 13
After ACE
inhibition
99 9
107±8 104±8
776 Dc 'Oliveira et al: Angiotensin in diabetes mellitus
limited substrate specificity of the ACE [10, 11]. For that reason,
we included an assessment of renal vascular responsiveness to
Ang II prior to and during ACE inhibition. In animals, bradykinin,
prostaglandins and nitric oxide blunt renal vascular responses to
Ang II [12]. If ACE inhibitor-induced renal vasodilation was
dominated by one or more of these mechanisms, we anticipated
that vasodilation would have been associated with further blunting
of the renal vascular response. On the other hand, if the ACE
inhibitor-induced renal vasodilation reflected a reduction in Ang
II formation, an enhancement of the renal vascular response was
anticipated. ACE and renin inhibitor-induced renal vasodilation
are associated with a quantitatively identical enhancement of the
renal vascular response to Ang II in normal subjects [13]. The
current data suggest that the ACE inhibitor-induced renal vaso-
dilation also reflects a reduction in Ang II formation in patients
with NIDDM. Indeed, as baseline renal vascular responsiveness to
Ang II in subjects on a high salt diet was substantially less than our
experience in normal humans [7, 13, 14], the vasodilator response
to enalapril can be thought of as having corrected baseline
blunting of the renal vascular response. Conversely, in normal
humans, enalapril did not enhance the renal vascular response to
Ang II when studies were performed in high salt balance [7]. We
can find only one study, that by Bjorck, who employed a similar
approach in patients with IDDM [3]. Similar to our finding in
NIDDM, Bjorck found PRA generally to be normal or high. On
the other hand, he found a normal renal vascular response to Ang
II infusion. Whether the difference in the findings reflects a
fundamental difference in Type I or Type II diabetes or details of
protocol, especially control of sodium intake and the use of
diuretics or difference in stage is not clear.
The renal hemodynamic abnormality included sparing of gb-
merular filtration rate, so that age-adjusted filtration fraction was
substantially higher in the patients with NIDDM than normoten-
sive controls. Again, this was corrected by ACE inhibition, as
renal plasma flow rose and GFR did not change. To the extent
that filtration fraction provides an index of hydrostatic pressure in
the glomerular capillaries, the observation that filtration fraction
was increased in subjects on a high salt diet, and that the increase
was attenuated significantly by ACE inhibition might have impli-
cations both for pathophysiobogy and for treatment, as has been
widely discussed [15—17].
An abnormality in the control of the kidney that is linked to the
state of sodium balance in patients with NIDDM is of some
interest, given earlier documentation to indicate that diabetes
might influence sodium handling, and that total body sodium is
expanded in patients with NIDDM who are ingesting an essen-
tially unrestricted salt intake [18, 19]. The greater weight gain
following a shift to a high salt diet in the NIDDM in this study
confirms and extends those observations. The subnormal suppres-
sion of the renin system is unlikely to represent occult volume
contraction. Caution is appropriate in interpreting the differences
between the subjects we studied on a high salt and low salt diet,
however, as different subjects participated in the two protocols,
although assignment to the protocols was random and the groups
appear to have been well-matched.
The rather low frequency of low-renin hypertension in this
patient population was not anticipated on the basis of early
reports that indicated suppression of the renin system to be
common in NIDDM [20, 21]. Prompted by this experience in a
rather small sample of the NIDDM population, we undertook an
analysis of a substantially larger sample with the same outcome:
low-renin hypertension was not especially common in our
NIDDM population who were free of nephropathy and were
recruited for investigation of hypertension [221. The decision to
separate the low renin patients for analysis was not data driven,
but rather was part of our original analysis plan, reflecting the
widely held view of the prevalence of the low renin state in
diabetes mellitus. The finding of a somewhat activated renin
system in patients on a high salt intake did not depend on
separation of the subgroups as analysis including the low renin
patient revealed a significant increase in PRA, plasma aldosterone
and in ACE inhibitor effectiveness despite the high salt diet. Thus,
the finding is not an artifact of analysis by subgroup. The
unambiguous blunting of the depressor response to the ACE
inhibitor in the patients with low renin hypertension was antici-
pated [23]. On the other hand, there are no reports with which to
compare the surprisingly robust renal vasodilator response to
enalapril in the three low-renin patients. That response did not
differ from the patients in whom the renin system appeared to be
normal.
The apparent autonomy of renin release despite a high salt diet
uncovered in this study is startling, given the longstanding interest
in the renin system in patients with diabetes mellitus [20, 21], as
reviewed extensively recently [3, 24, 25]. The only comparable
study that we have been able to identify is the report by Trujillo et
al [26], who examined patients with Type II diabetes and normal
controls with shifts in salt intake. They did not find poorly
suppressible renin levels on a high salt diet. One possible expla-
nation is the fact that their normal controls, average age 48 years,
were significantly younger than their hypertensive diabetics, who
averaged 62 years [26]. Race might be another factor [24]. This
study largely involved Caucasian participants, and no mention was
made of ethnicity and race in the earlier study [26].
NIDDM is frequently characterized by obesity, and this study
was no exception [27]. Mean BMI was 30, exceeding the normal
subjects substantially. One important implication of the increased
BMI in NIDDM involves the normalization procedure for renal
hemodynamie measurements. There is a longstanding convention
of normalization of renal hemodynamic measures to body surface
area, to adjust for differences in body size. Concern has been
expressed recently that this correction might lead to an apparent
reduction in renal perfusion and GFR [28]. An increase in renal
perfusion and filtration rate, a form of "hyperfiltration," has been
reported in some patients with NIDDM [29, 30] and was not
found in this study. At least in part the difference may be more
apparent than real, as we employed the usual convention, and
normalized for body surface area. None of the important conclu-
sions reflect the normalization procedure.
Our entry criteria were identical to those employed in earlier
studies on hypertension 1311, and so patients with azotemia or
gross proteinuria were excluded. Thus, frank nephropathy was not
identified in this group of patients. Whether the observations
made in this study arc applicable to the patient with overt diabetic
nephropathy will require investigation. The last fifteen years have
seen an explosive increase in the frequency of diabetic nephrop-
athy, to become the leading cause of end-stage renal disease in
modern societies [32]. Although ii is likely that pathogenesis is
multifactorial, the altered regulatory mechanisms identified in this
study merit pursuit. Activation of the renal renin system has been
documented with the more direct techniques that can be applied
in animal models of diabetes [33—35]. ACE inhibition is unequiv-
ocally effective in IDDM, and may well be in NIDDM [36—38].
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Our findings may provide a rationale for that effectiveness.
Moreover, the potentiation of renal vascular responses to Ang II
after enalapril—suggesting that enalapril's action reflected reduced
Ang II formation—bodes well for newer agents that block renin's
action on the Ang II receptor.
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